Florida 2025 Regular Session

Florida House Bill H1347 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3	HB 1347 2025
4	4
5	5
6	6
7	7	CODING: Words stricken are deletions; words underlined are additions.
8	8	hb1347-00
9	9	Page 1 of 25
10	10	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
11	11
12	12
13	13
14	14	A bill to be entitled 1
15	15	An act relating to cancer treatment and research; 2
16	16	amending s. 381.915, F.S.; authorizing the Department 3
17	17	of Health to establish the Florida Cancer Research 4
18	18	Network; revising definitions; making grant funds 5
19	19	available; providing requirements and criteria for 6
20	20	grant fund applicants; providing criteria for awarding 7
21	21	grant funds; providing data reporting requirements for 8
22	22	health care providers; requiring certain data for 9
23	23	collection; providing requirements for the collection 10
24	24	of data; creating an online repository for best 11
25	25	practices on the Florida Cancer Connect website; 12
26	26	authorizing the Cancer Connect Collaborative to 13
27	27	oversee the Florida Cancer Research Network; creatin g 14
28	28	subcommittees; requiring the Cancer Connect 15
29	29	Collaborative to annually submit a specified report to 16
30	30	the Governor and the Legislature; creating the Cancer 17
31	31	Connect Collaborative Incubator; providing an 18
32	32	effective date. 19
33	33	20
34	34	Be It Enacted by the Legislature o f the State of Florida: 21
35	35	22
36	36	Section 1. Section 381.915, Florida Statutes, is amended 23
37	37	to read: 24
38	38	381.915 Casey DeSantis Cancer Research Program. — 25
39	39
40	40	HB 1347 2025
41	41
42	42
43	43
44	44	CODING: Words stricken are deletions; words underlined are additions.
45	45	hb1347-00
46	46	Page 2 of 25
47	47	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
48	48
49	49
50	50
51	51	(1) This section may be cited as the "Casey DeSantis 26
52	52	Cancer Research Act." 27
53	53	(2) The Casey DeSantis Cancer R esearch Program is 28
54	54	established to enhance the quality and competitiveness of cancer 29
55	55	care in this state, further a statewide biomedical research 30
56	56	strategy directly responsive to the health needs of Florida's 31
57	57	citizens, capitalize on the potential educational opportunities 32
58	58	available to its students, and promote the provision of high -33
59	59	quality, innovative health care for persons undergoing cancer 34
60	60	treatment in this state. The department shall: 35
61	61	(a) Make payments to cancer centers recognized by the 36
62	62	National Cancer Institute (NCI) at the National Institutes of 37
63	63	Health as NCI-designated cancer centers or NCI -designated 38
64	64	comprehensive cancer centers, and cancer centers working toward 39
65	65	achieving NCI designation. The department shall distribute funds 40
66	66	to participating cancer centers on a quarterly basis during each 41
67	67	fiscal year for which an appropriation is made. 42
68	68	(a)(b) Make cancer innovation grant funding available 43
69	69	through the Cancer Innovation Fund under subsection (9) to 44
70	70	health care providers and facilities that demonstra te excellence 45
71	71	in patient-centered cancer treatment or research. 46
72	72	(b) Establish the Florida Cancer Research Network within 47
73	73	the department, under the direction of the Cancer Connect 48
74	74	Collaborative, to promote the research and development of 49
75	75	innovative cancer treatments through the expansion of grant 50
76	76
77	77	HB 1347 2025
78	78
79	79
80	80
81	81	CODING: Words stricken are deletions; words underlined are additions.
82	82	hb1347-00
83	83	Page 3 of 25
84	84	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
85	85
86	86
87	87
88	88	opportunities, enhance patient access to emerging cancer 51
89	89	therapies by extending research programs into rural and 52
90	90	underserved areas, track patient data to evaluate outcomes and 53
91	91	develop novel approaches to cancer ca re by increasing the 54
92	92	metrics collected by the Florida Cancer Data System, and 55
93	93	identify and implement best practices to ensure the delivery of 56
94	94	high-quality, effective cancer treatment. 57
95	95	(3) On or before September 15 of each year, the department 58
96	96	shall calculate an allocation fraction to be used for 59
97	97	distributing funds to participating cancer centers. On or before 60
98	98	the final business day of each quarter of the state fiscal year, 61
99	99	the department shall distribute to each participating cancer 62
100	100	center one-fourth of that cancer center's annual allocation 63
101	101	calculated under subsection (6). The allocation fraction for 64
102	102	each participating cancer center is based on the cancer center's 65
103	103	tier-designated weight under subsection (4) multiplied by each 66
104	104	of the following allocation f actors based on activities in this 67
105	105	state: number of reportable cases, peer -review costs, and 68
106	106	biomedical education and training. 69
107	107	(3) As used in this section, the term: 70
108	108	(a) "Biomedical education and training" means instruction 71
109	109	that is offered to a studen t who is enrolled in a biomedical 72
110	110	research program at an affiliated university as a medical 73
111	111	student or a student in a master's or doctoral degree program, 74
112	112	or who is a resident physician trainee or postdoctoral trainee 75
113	113
114	114	HB 1347 2025
115	115
116	116
117	117
118	118	CODING: Words stricken are deletions; words underlined are additions.
119	119	hb1347-00
120	120	Page 4 of 25
121	121	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
122	122
123	123
124	124
125	125	in such program. An affiliated univers ity biomedical research 76
126	126	program must be accredited or approved by a nationally 77
127	127	recognized agency and offered through an institution accredited 78
128	128	by an accrediting agency or association recognized by the 79
129	129	database created and maintained by the United States De partment 80
130	130	of Education. Full-time equivalency for trainees shall be 81
131	131	prorated for training received in oncologic sciences and 82
132	132	oncologic medicine. 83
133	133	(b) "Cancer center" means a comprehensive center with at 84
134	134	least one geographic site in the state, a freestandin g center 85
135	135	located in the state, a center situated within an academic 86
136	136	institution, or a Florida -based formal research -based consortium 87
137	137	under centralized leadership that has achieved NCI designation 88
138	138	or is prepared to achieve NCI designation by June 30, 2025, or 89
139	139	has received a Cancer Center of Excellence Award 2024. 90
140	140	(c) "Florida-based" means that a health care provider or 91
141	141	facility that is physically located and provides services in 92
142	142	this state, and the cancer center's actual or sought designated 93
143	143	status is or would be recognized by the NCI as primarily located 94
144	144	in Florida and not in another state. 95
145	145	(4) The Florida Cancer Research Network shall make grant 96
146	146	funding available to Florida -based health care providers and 97
147	147	entities that conduct or plan to conduct research and 98
148	148	development of innovative cancer treatments for adult or 99
149	149	pediatric patients or prov ide workforce and post -doctoral 100
150	150
151	151	HB 1347 2025
152	152
153	153
154	154
155	155	CODING: Words stricken are deletions; words underlined are additions.
156	156	hb1347-00
157	157	Page 5 of 25
158	158	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
159	159
160	160
161	161
162	162	fellowship practitioners in the prevention, screening, 101
163	163	diagnosis, or treatment of cancer. 102
164	164	(a) Grant funding available through the Florida Cancer 103
165	165	Research Network consists of funds appropriated by the 104
166	166	Legislature through th e Casey DeSantis Cancer Research Program. 105
167	167	(b) A licensed or certified health care provider, 106
168	168	facility, or entity shall meet the following criteria to be 107
169	169	eligible for grant funding through the Florida Cancer Research 108
170	170	Network: 109
171	171	1. Operate as a Florida -based cancer center; 110
172	172	2. Operate a licensed hospital that has a minimum of 30 111
173	173	percent of current cancer patients that reside in rural or 112
174	174	underserved areas; 113
175	175	3. Operate a licensed health care clinic or facility that 114
176	176	employs or contracts with at least one lice nsed physician who 115
177	177	specializes in oncology and delivers chemotherapy treatments for 116
178	178	cancer; 117
179	179	4. Operate a licensed facility that employs or contracts 118
180	180	with at least one licensed physician who specializes in oncology 119
181	181	and that delivers radiation therapy trea tments for cancer; 120
182	182	5. Operate as a rural hospital as defined in s. 121
183	183	395.602(2); 122
184	184	6. Operate as a critical access hospital as defined in s. 123
185	185	408.07; 124
186	186
187	187	HB 1347 2025
188	188
189	189
190	190
191	191	CODING: Words stricken are deletions; words underlined are additions.
192	192	hb1347-00
193	193	Page 6 of 25
194	194	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
195	195
196	196
197	197
198	198	7. Operate as a specialty hospital as defined in s. 125
199	199	395.002(28)(a) that serves patients up to 18 years o f age; 126
200	200	8. Engage in biomedical research intended to develop 127
201	201	therapies, medical pharmaceuticals, treatment protocols, or 128
202	202	medical procedures intended to cure cancer or improve a 129
203	203	patient's quality of life; or 130
204	204	9. Educate or train students, post -doctoral fellows, or 131
205	205	licensed or certified health care practitioners in the 132
206	206	screening, diagnosis, or treatment of cancer. 133
207	207	(c) The department shall oversee the distribution of grant 134
208	208	funds awarded to health care providers and entities through the 135
209	209	Florida Cancer Resea rch Network. The department shall distribute 136
210	210	grant funds on a quarterly basis during each fiscal year for 137
211	211	which an appropriation is made. 138
212	212	(d) Eligible health care providers or entities must submit 139
213	213	applications to the department by July 1 of each year to be 140
214	214	considered for Florida Cancer Research Network grant fund 141
215	215	awards. 142
216	216	(e) The department shall evaluate applications submitted 143
217	217	by health care providers and entities. The department shall 144
218	218	consider each applicant's ability to: 145
219	219	1. Achieve objectives and ou tcomes. 146
220	220	2. Identify populations, types of cancer, and short and 147
221	221	long-term goals and outcomes. 148
222	222
223	223	HB 1347 2025
224	224
225	225
226	226
227	227	CODING: Words stricken are deletions; words underlined are additions.
228	228	hb1347-00
229	229	Page 7 of 25
230	230	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
231	231
232	232
233	233
234	234	3. Expand access to cancer screenings, diagnostic 149
235	235	services, or treatment to rural or underserved populations. 150
236	236	4. Research or implement innovative cancer tre atments or 151
237	237	screenings or diagnostic services, and 152
238	238	5. Research innovative medical pharmaceutical treatments 153
239	239	to cure cancer or improve the quality of life of cancer 154
240	240	patients. 155
241	241	6. Collaborate with other health care providers or 156
242	242	entities to deliver cancer s creenings, diagnostic services, or 157
243	243	treatments; participate in phase III clinical trials of 158
244	244	experimental cancer treatments; or conduct biomedical research 159
245	245	intended to cure cancer or improve the quality of life of cancer 160
246	246	patients. 161
247	247	7. Educate or train stude nts, post-doctoral fellows, or 162
248	248	licensed or certified health care practitioners in the 163
249	249	screening, diagnosis, or treatment of cancer. 164
250	250	(f) The department shall deem an application qualified or 165
251	251	unqualified based on its evaluation. 166
252	252	(g)1. On or before Octobe r 1 of each year, the department 167
253	253	shall calculate an allocation of grant funds for health care 168
254	254	providers or entities that submit a qualified application. 169
255	255	2. The department shall contract with grant awardees to 170
256	256	conduct research to develop innovative cancer treatments, 171
257	257	procedures, therapeutic services, medical pharmaceuticals, or 172
258	258	provide biomedical education and training in the care and 173
259	259
260	260	HB 1347 2025
261	261
262	262
263	263
264	264	CODING: Words stricken are deletions; words underlined are additions.
265	265	hb1347-00
266	266	Page 8 of 25
267	267	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
268	268
269	269
270	270
271	271	treatment of cancer. 174
272	272	(5)(a) The department shall expand the Florida Cancer Data 175
273	273	System to include data on patient outcome s and quality of care 176
274	274	submitted by licensed health care providers that diagnose, 177
275	275	treat, and screen for cancer. 178
276	276	(b) Licensed health care providers that diagnose, treat, 179
277	277	and screen for cancer must report to the Florida Cancer Data 180
278	278	System data that includes all of the following: 181
279	279	1. Patient-reported outcome measures that collect patient 182
280	280	reports on symptoms, quality of life, quality of cancer care, 183
281	281	and cancer treatment outcomes. 184
282	282	2. Quality of care measures that identify and report all 185
283	283	of the following: 186
284	284	a. Cancer screening rates. 187
285	285	b. Timeliness of diagnosis and treatment. 188
286	286	c. Clinical guidelines adherence. 189
287	287	d. Survival rates. 190
288	288	e. Tumor response rates. 191
289	289	f. Progression-free survival rates. 192
290	290	g. Disease-free survival rates. 193
291	291	h. Treatment complication ra tes. 194
292	292	i. Percentage of cancer patients receiving palliative or 195
293	293	hospice care, and coordination of care. 196
294	294	j. Provider volume and expertise. 197
295	295	k. Adverse event monitoring. 198
296	296
297	297	HB 1347 2025
298	298
299	299
300	300
301	301	CODING: Words stricken are deletions; words underlined are additions.
302	302	hb1347-00
303	303	Page 9 of 25
304	304	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
305	305
306	306
307	307
308	308	l. Treatment compliance and persistence. 199
309	309	m. Biomarker response. 200
310	310	n. Long-term outcomes and survivorship. 201
311	311	(6) The department shall create an online repository on 202
312	312	the Florida Cancer Connect website of best practices for cancer 203
313	313	treatment, screening, diagnosis, prevention, and survivorship. 204
314	314	The repository shall include best practices fo r all of the 205
315	315	following: 206
316	316	(a) Screening and risk reduction of cancer. 207
317	317	(b) Clinical management of cancer. 208
318	318	(c) Phases I-IV clinical trials for cancer treatments. 209
319	319	(d) Care plans for patients receiving post -cancer 210
320	320	treatment. 211
321	321	(d) "Peer-review costs" means the total annual direct 212
322	322	costs for peer-reviewed cancer-related research projects, 213
323	323	consistent with reporting guidelines provided by the NCI, for 214
324	324	the most recent annual reporting period available. 215
325	325	(e) "Reportable cases" means cases of cancer in which a 216
326	326	cancer center is involved in the diagnosis, evaluation of the 217
327	327	diagnosis, evaluation of the extent of cancer spread at the time 218
328	328	of diagnosis, or administration of all or any part of the first 219
329	329	course of therapy for the most recent annual reporting period 220
330	330	available. Cases relating to patients enrolled in institutional 221
331	331	or investigator-initiated interventional clinical trials shall 222
332	332	be weighted at 1.2 relative to other cases weighted at 1.0. 223
333	333
334	334	HB 1347 2025
335	335
336	336
337	337
338	338	CODING: Words stricken are deletions; words underlined are additions.
339	339	hb1347-00
340	340	Page 10 of 25
341	341	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
342	342
343	343
344	344
345	345	Determination of institutional or investigator -initiated 224
346	346	interventional clinical trials must be consistent with reporting 225
347	347	guidelines provided by the NCI. 226
348	348	(4) Tier designations and corresponding weights within the 227
349	349	Casey DeSantis Cancer Research Program are as follows: 228
350	350	(a) Tier 1: NCI-designated comprehensive cancer centers, 229
351	351	which shall be weighted at 1.5. 230
352	352	(b) Tier 2: NCI-designated cancer centers, which shall be 231
353	353	weighted at 1.25. 232
354	354	(c) Tier 3: Cancer centers seeking designation as either a 233
355	355	NCI-designated cancer center or NCI -designated comprehensive 234
356	356	cancer center, which sh all be weighted at 1.0. 235
357	357	1. A cancer center shall meet the following minimum 236
358	358	criteria to be considered eligible for Tier 3 designation in any 237
359	359	given fiscal year: 238
360	360	a. Conducting cancer -related basic scientific research and 239
361	361	cancer-related population scienti fic research; 240
362	362	b. Offering and providing the full range of diagnostic and 241
363	363	treatment services on site, as determined by the Commission on 242
364	364	Cancer of the American College of Surgeons; 243
365	365	c. Hosting or conducting cancer -related interventional 244
366	366	clinical trials that are registered with the NCI's Clinical 245
367	367	Trials Reporting Program; 246
368	368	d. Offering degree-granting programs or affiliating with 247
369	369	universities through degree -granting programs accredited or 248
370	370
371	371	HB 1347 2025
372	372
373	373
374	374
375	375	CODING: Words stricken are deletions; words underlined are additions.
376	376	hb1347-00
377	377	Page 11 of 25
378	378	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
379	379
380	380
381	381
382	382	approved by a nationally recognized agency and offered through 249
383	383	the center or through the center in conjunction with another 250
384	384	institution accredited by an accrediting agency or association 251
385	385	recognized by the database created and maintained by the United 252
386	386	States Department of Education; 253
387	387	e. Providing training to clinical trai nees, medical 254
388	388	trainees accredited by the Accreditation Council for Graduate 255
389	389	Medical Education or the American Osteopathic Association, and 256
390	390	postdoctoral fellows recently awarded a doctorate degree; and 257
391	391	f. Having more than $5 million in annual direct costs 258
392	392	associated with their total NCI peer -reviewed grant funding. 259
393	393	2. The General Appropriations Act or accompanying 260
394	394	legislation may limit the number of cancer centers which shall 261
395	395	receive Tier 3 designations or provide additional criteria for 262
396	396	such designation. 263
397	397	3. A cancer center's participation in Tier 3 may not 264
398	398	extend beyond June 30, 2024. 265
399	399	4. A cancer center that qualifies as a designated Tier 3 266
400	400	center under the criteria provided in subparagraph 1. by July 1, 267
401	401	2014, is authorized to pursue NCI designation as a cancer center 268
402	402	or a comprehensive cancer center until June 30, 2024. 269
403	403	(5) The department shall use the following formula to 270
404	404	calculate a participating cancer center's allocation fraction: 271
405	405	CAF = [0.4 x (CRC÷TCRC)]+[0.3 x (CPC÷TCPC)]+[0.3 x (CBE÷TCBE)] 272
406	406	Where: 273
407	407
408	408	HB 1347 2025
409	409
410	410
411	411
412	412	CODING: Words stricken are deletions; words underlined are additions.
413	413	hb1347-00
414	414	Page 12 of 25
415	415	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
416	416
417	417
418	418
419	419	CAF = A cancer center's allocation fraction. 274
420	420	CRC = A cancer center's tier -weighted reportable cases. 275
421	421	TCRC = The total tier -weighted reportable cases for all 276
422	422	cancer centers. 277
423	423	CPC = A cancer center's tier -weighted peer-review costs. 278
424	424	TCPC = The total tier-weighted peer-review costs for all 279
425	425	cancer centers. 280
426	426	CBE = A cancer center's tier -weighted biomedical education 281
427	427	and training. 282
428	428	TCBE = The total tier -weighted biomedical education and 283
429	429	training for all cancer centers. 284
430	430	(6) A cancer center's annual allocation shall be 285
431	431	calculated by multiplying the funds appropriated for the Casey 286
432	432	DeSantis Cancer Research Program in the General Appropriations 287
433	433	Act by that cancer center's allocation fraction. If the 288
434	434	calculation results in an annual allocation that is le ss than 289
435	435	$16 million, that cancer center's annual allocation shall be 290
436	436	increased to a sum equaling $16 million, with the additional 291
437	437	funds being provided proportionally from the annual allocations 292
438	438	calculated for the other participating cancer centers. 293
439	439	(7) The amount of $37,771,257 from the total funds 294
440	440	appropriated in the General Appropriations Act for the Casey 295
441	441	DeSantis Cancer Research Program shall be excluded from the 296
442	442	annual allocation fraction calculation under subsection (5). The 297
443	443	excluded amount shall be distributed to participating cancer 298
444	444
445	445	HB 1347 2025
446	446
447	447
448	448
449	449	CODING: Words stricken are deletions; words underlined are additions.
450	450	hb1347-00
451	451	Page 13 of 25
452	452	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
453	453
454	454
455	455
456	456	centers in the same proportion as determined by the allocation 299
457	457	fraction calculation. 300
458	458	(7)(8) The Cancer Connect Collaborative, a council as 301
459	459	defined in s. 20.03, is created within the department to advise 302
460	460	the department and the Legislature on developing a holistic 303
461	461	approach to the state's efforts to fund cancer research, cancer 304
462	462	facilities, and treatments for cancer patients. The 305
463	463	collaborative may make recommendations on proposed legislation, 306
464	464	proposed rules, best practices , data collection and reporting, 307
465	465	issuance of grant funds, and other proposals for state policy 308
466	466	relating to cancer research or treatment. 309
467	467	(a) The Surgeon General shall serve as an ex officio, 310
468	468	nonvoting member and shall serve as the chair. 311
469	469	(b) The collaborative shall be composed of the following 312
470	470	voting members, to be appointed by September 1, 2024: 313
471	471	1. Two members appointed by the Governor, one member 314
472	472	appointed by the President of the Senate, and one member 315
473	473	appointed by the Speaker of the House of Repres entatives, based 316
474	474	on the criteria of this subparagraph. The appointing officers 317
475	475	shall make their appointments prioritizing members who have the 318
476	476	following experience or expertise: 319
477	477	a. The practice of a health care profession specializing 320
478	478	in oncology clinical care or research; 321
479	479	b. The development of preventive and therapeutic 322
480	480	treatments to control cancer; 323
481	481
482	482	HB 1347 2025
483	483
484	484
485	485
486	486	CODING: Words stricken are deletions; words underlined are additions.
487	487	hb1347-00
488	488	Page 14 of 25
489	489	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
490	490
491	491
492	492
493	493	c. The development of innovative research into the causes 324
494	494	of cancer, the development of effective treatments for persons 325
495	495	with cancer, or cures for cancer ; or 326
496	496	d. Management-level experience with a cancer center 327
497	497	licensed under chapter 395. 328
498	498	2. One member who is a resident of this state who can 329
499	499	represent the interests of cancer patients in this state, 330
500	500	appointed by the Governor. 331
501	501	(c) The terms of appointees under paragraph (b) shall be 332
502	502	for 2 years unless otherwise specified. However, to achieve 333
503	503	staggered terms, the initial appointees under that paragraph 334
504	504	shall serve 3 years for their first term. These appointees may 335
505	505	be reappointed for no more than four consecutive terms. 336
506	506	(d) Any vacancy occurring on the collaborative must be 337
507	507	filled in the same manner as the original appointment. Any 338
508	508	member who is appointed to fill a vacancy occurring because of 339
509	509	death, resignation, or ineligibility for membership s hall serve 340
510	510	only for the unexpired term of the member's predecessor. 341
511	511	(e) Members whose terms have expired may continue to serve 342
512	512	until replaced or reappointed, but for no more than 6 months 343
513	513	after the expiration of their terms. 344
514	514	(f) Members shall serve wit hout compensation but are 345
515	515	entitled to reimbursement for per diem and travel expenses 346
516	516	pursuant to s. 112.061. 347
517	517	(g) The collaborative shall meet as necessary, but at 348
518	518
519	519	HB 1347 2025
520	520
521	521
522	522
523	523	CODING: Words stricken are deletions; words underlined are additions.
524	524	hb1347-00
525	525	Page 15 of 25
526	526	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
527	527
528	528
529	529
530	530	least quarterly, at the call of the chair. A majority of the 349
531	531	members of the collaborative c onstitutes a quorum, and a meeting 350
532	532	may not be held with less than a quorum present. In order to 351
533	533	establish a quorum, the collaborative may conduct its meetings 352
534	534	through teleconference or other electronic means. The 353
535	535	affirmative vote of a majority of the membe rs of the 354
536	536	collaborative present is necessary for any official action by 355
537	537	the collaborative. 356
538	538	(h) The collaborative shall oversee the administration and 357
539	539	functions of the Florida Cancer Research Network. 358
540	540	(i)1. The following subcommittees are created to rev iew 359
541	541	and evaluate performance of and to advise and support the 360
542	542	collaborative on the oversight of the Florida Cancer Research 361
543	543	Network. Each subcommittee shall have eight members appointed by 362
544	544	the State Surgeon General and be chaired by a current member of 363
545	545	the collaborative: 364
546	546	a. Research Funding Subcommittee. 365
547	547	b. Recruitment Funding Subcommittee. 366
548	548	c. Infrastructure and Technology Funding Subcommittee. 367
549	549	d. Program Development Funding Subcommittee. 368
550	550	2. Appointees shall serve for a 2 -year term. However, to 369
551	551	achieve staggered terms, the initial appointees shall serve for 370
552	552	3 years for their first term. Such appointees may be reappointed 371
553	553	for no more than 4 consecutive terms. 372
554	554
555	555	HB 1347 2025
556	556
557	557
558	558
559	559	CODING: Words stricken are deletions; words underlined are additions.
560	560	hb1347-00
561	561	Page 16 of 25
562	562	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
563	563
564	564
565	565
566	566	3. Members shall serve without compensation but are 373
567	567	entitled to reimbursement for per die m and travel expenses 374
568	568	pursuant to s. 112.061. 375
569	569	(j) The collaborative shall prepare an annual report due 376
570	570	to the Governor, President of the Senate, and Speaker of the 377
571	571	House of Representatives by December 1, 2025, and each 378
572	572	succeeding year that identifies and evaluates performance and 379
573	573	effect of the Florida Cancer Research Network on cancer 380
574	574	treatment, screening, diagnosis, prevention, practitioner and 381
575	575	workforce education, and survivorship. The report shall include 382
576	576	the following: 383
577	577	1. A needs assessment that ana lyzes current practices, 384
578	578	patient outcomes, and gaps in care throughout the state. 385
579	579	2. A review of current evidence -based clinical guidelines 386
580	580	released by reputable clinical associations. 387
581	581	3. A literature review of cancer treatment studies 388
582	582	published during the previous calendar years. 389
583	583	4. An assessment of current and innovative cancer 390
584	584	screening and diagnostic services. 391
585	585	5. Amount of grant funds awarded to each awardee. 392
586	586	6. Descriptions of each awardee's research or project that 393
587	587	includes the following: 394
588	588	a. Goals or projected outcomes 395
589	589	b. Population to be served 396
590	590	c. Research methods or project implementation plan 397
591	591
592	592	HB 1347 2025
593	593
594	594
595	595
596	596	CODING: Words stricken are deletions; words underlined are additions.
597	597	hb1347-00
598	598	Page 17 of 25
599	599	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
600	600
601	601
602	602
603	603	7. An assessment of awardees of grant funds that evaluates 398
604	604	performance toward achieving objectives specified in their grant 399
605	605	funds applications. 400
606	606	8. Case studies of Florida patients who have received 401
607	607	cancer treatment and patients who are receiving post -cancer 402
608	608	treatment. 403
609	609	9. Recommendations for best practices to be implemented by 404
610	610	health care providers in Florida that diagnose, treat, and 405
611	611	screen for cancer. 406
612	612	(k) The committee shall meet quarterly or at the call of 407
613	613	the chair. A majority of the members of the committee 408
614	614	constitutes a quorum, and a meeting may not be held with less 409
615	615	than a quorum present. In order to establish a quorum, the 410
616	616	committee may conduct its meetings through teleconference or 411
617	617	other electronic means. The affirmative vote of a majority of 412
618	618	the members of the committee present is necessary for any 413
619	619	official action by the committee. 414
620	620	(h) The collaborative shall develop a long -range 415
621	621	comprehensive plan for the Casey DeSantis Cancer Research 416
622	622	Program. In the development of the plan, the collaborative must 417
623	623	solicit input from cancer centers, research institutions, 418
624	624	biomedical education institutions, hospitals, and medical 419
625	625	providers. The collaborative shall submit the plan to the 420
626	626	Governor, the President of the Senate, and the Speaker of the 421
627	627	House of Representatives no later than December 1, 2024. The 422
628	628
629	629	HB 1347 2025
630	630
631	631
632	632
633	633	CODING: Words stricken are deletions; words underlined are additions.
634	634	hb1347-00
635	635	Page 18 of 25
636	636	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
637	637
638	638
639	639
640	640	plan must include, but need not be limited to, all of the 423
641	641	following components: 424
642	642	1. Expansion of grant fund opportunities to include a 425
643	643	broader pool of Florida -based cancer centers, research 426
644	644	institutions, biomedical education institutions, hospitals, and 427
645	645	medical providers to receive funding through the Cancer 428
646	646	Innovation Fund. 429
647	647	2. An evaluation to determine metrics that focus on 430
648	648	patient outcomes, quality of care, and efficacy of treatment. 431
649	649	3. A compilation of best practices relating to cancer 432
650	650	research or treatment. 433
651	651	(l)(i) The department shall provide reasonable and 434
652	652	necessary support sta ff and materials to assist the 435
653	653	collaborative in the performance of its duties. 436
654	654	(m)1.(j)1. As used in this paragraph, the term 437
655	655	"proprietary business information" means information that: 438
656	656	a. Is owned or controlled by the applicant; 439
657	657	b. Is intended to be private and is treated by the 440
658	658	applicant as private; 441
659	659	c. Has not been disclosed except as required by law or a 442
660	660	private agreement that provides that the information will not be 443
661	661	released to the public; 444
662	662	d. Is not readily available or ascertainable through 445
663	663	proper means from another source in the same configuration as 446
664	664	received by the collaborative; 447
665	665
666	666	HB 1347 2025
667	667
668	668
669	669
670	670	CODING: Words stricken are deletions; words underlined are additions.
671	671	hb1347-00
672	672	Page 19 of 25
673	673	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
674	674
675	675
676	676
677	677	e. Affects competitive interests, and the disclosure of 448
678	678	such information would impair the competitive advantage of the 449
679	679	applicant; and 450
680	680	f. Is explicitly identifie d or clearly marked as 451
681	681	proprietary business information. 452
682	682	2. Proprietary business information held by the department 453
683	683	or the collaborative is confidential and exempt from s. 454
684	684	119.07(1) and s. 24(a), Art. I of the State Constitution. This 455
685	685	exemption does not apply to information contained in final 456
686	686	recommendations of the collaborative. 457
687	687	3. Portions of a meeting of the collaborative during which 458
688	688	confidential and exempt proprietary business information is 459
689	689	discussed are exempt from s. 286.011 and s. 24(b), Art. I of the 460
690	690	State Constitution. The closed portion of a meeting must be 461
691	691	recorded, and the recording must be maintained by the 462
692	692	collaborative. The recording is confidential and exempt from s. 463
693	693	119.07(1) and s. 24(a), Art. I of the State Constitution. 464
694	694	4.a. Proprietary business information made confidential 465
695	695	and exempt under subparagraph 2. may be disclosed with the 466
696	696	express written consent of the applicant to whom the information 467
697	697	pertains, or the applicant's legally authorized representative, 468
698	698	or pursuant to a court order upon a showing of good cause. 469
699	699	b. Recordings of those portions of exempt meetings which 470
700	700	are made confidential and exempt under subparagraph 3. may be 471
701	701	disclosed to the department or pursuant to a court order upon a 472
702	702
703	703	HB 1347 2025
704	704
705	705
706	706
707	707	CODING: Words stricken are deletions; words underlined are additions.
708	708	hb1347-00
709	709	Page 20 of 25
710	710	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
711	711
712	712
713	713
714	714	showing of good cause. 473
715	715	5. This paragraph is subject to the Open Government Sunset 474
716	716	Review Act in accordance with s. 119.15 and shall stand repealed 475
717	717	on October 2, 2029, unless reviewed and saved from repeal 476
718	718	through reenactment by the Legislature. 477
719	719	(8)(9) The collaborative shall advise the department on 478
720	720	the awarding of grants issued through the Cancer Innovation 479
721	721	Fund. During any fiscal year for which funds are appropriated to 480
722	722	the fund, the collaborative shall review all submitted grant 481
723	723	applications and make recommendations to the department for 482
724	724	awarding grants to support innovative cancer research and 483
725	725	treatment models, including emerging research and treatment 484
726	726	trends and promising treatments that may serve as catalysts for 485
727	727	further research and treatments. The department shall make the 486
728	728	final grant allocation awards. The collaborative shall give 487
729	729	priority to applications seeking to expand the reach of 488
730	730	innovative cancer treatment models into underserved areas of 489
731	731	this state. 490
732	732	(9)(10) Beginning July 1, 2025, and each year thereafter, 491
733	733	the department, in conjunction with participating cancer 492
734	734	centers, shall submit a report to the Cancer Control and 493
735	735	Research Advisory Council and the collaborative on specific 494
736	736	metrics relating to cancer mortality and external funding for 495
737	737	cancer-related research in this s tate. If a cancer center does 496
738	738	not endorse this report or produce an equivalent independent 497
739	739
740	740	HB 1347 2025
741	741
742	742
743	743
744	744	CODING: Words stricken are deletions; words underlined are additions.
745	745	hb1347-00
746	746	Page 21 of 25
747	747	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
748	748
749	749
750	750
751	751	report, the cancer center is ineligible to receive program 498
752	752	funding for 1 year. The department must submit this annual 499
753	753	report, and any equivalent independent reports, to the Governor, 500
754	754	the President of the Senate, and the Speaker of the House of 501
755	755	Representatives no later than September 15 of each year the 502
756	756	report or reports are submitted by the department. The report 503
757	757	must include: 504
758	758	(a) An analysis of trending age -adjusted cancer mortality 505
759	759	rates in the state, which must include, at a minimum, overall 506
760	760	age-adjusted mortality rates for cancer statewide and age -507
761	761	adjusted mortality rates by age group, geographic region, and 508
762	762	type of cancer, which must include, at a minimum: 509
763	763	1. Lung cancer. 510
764	764	2. Pancreatic cancer. 511
765	765	3. Sarcoma. 512
766	766	4. Melanoma. 513
767	767	5. Leukemia and myelodysplastic syndromes. 514
768	768	6. Brain cancer. 515
769	769	7. Breast cancer. 516
770	770	(b) Identification of trends in overall federal funding, 517
771	771	broken down by institutional source, for cancer -related research 518
772	772	in the state. 519
773	773	(c) A list and narrative description of interinstitutional 520
774	774	collaboration among participating cancer centers, which may 521
775	775	include grants received by participating cancer centers in 522
776	776
777	777	HB 1347 2025
778	778
779	779
780	780
781	781	CODING: Words stricken are deletions; words underlined are additions.
782	782	hb1347-00
783	783	Page 22 of 25
784	784	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
785	785
786	786
787	787
788	788	collaboration, a comparison of such grants i n proportion to the 523
789	789	grant totals for each cancer center, a catalog of retreats and 524
790	790	progress seed grants using state funds, and targets for 525
791	791	collaboration in the future and reports on progress regarding 526
792	792	such targets where appropriate. 527
793	793	(10)(11) Beginning July 1, 2024, each allocation agreement 528
794	794	issued by the department relating to cancer center payments 529
795	795	under subsection (2) must include all of the following: 530
796	796	(a) A line-item budget narrative documenting the annual 531
797	797	allocation of funds to a cancer center. 532
798	798	(b) A cap on the annual award of 15 percent for 533
799	799	administrative expenses. 534
800	800	(c) A requirement for the cancer center to submit 535
801	801	quarterly reports of all expenditures made by the cancer center 536
802	802	with funds received through the Casey DeSantis Cancer Research 537
803	803	Program. 538
804	804	(d) A provision to allow the department and other state 539
805	805	auditing bodies to audit all financial records, supporting 540
806	806	documents, statistical records, and any other documents 541
807	807	pertinent to the allocation agreement. 542
808	808	(e) A provision requiring the annual re porting of outcome 543
809	809	data and protocols used in achieving those outcomes. 544
810	810	(11) The Legislature recognizes that nationally, targeted 545
811	811	areas of cancer research require increased resources and that 546
812	812	Florida should become a leader in promoting research 547
813	813
814	814	HB 1347 2025
815	815
816	816
817	817
818	818	CODING: Words stricken are deletions; words underlined are additions.
819	819	hb1347-00
820	820	Page 23 of 25
821	821	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
822	822
823	823
824	824
825	825	opportunities for these targeted areas. Floridians should not 548
826	826	have to leave the state to receive the most advanced cancer care 549
827	827	and treatment. To meet this need, the Legislature is authorizing 550
828	828	the creation of the Cancer Connect Collaborative Research 551
829	829	Incubator to identify and provide funding for a targeted area of 552
830	830	cancer research for a 5 -year period. 553
831	831	(12) The collaborative shall evaluate the present state of 554
832	832	cancer research in Florida and the United States and submit a 555
833	833	report to the Governor, President of the Senat e, and Speaker of 556
834	834	the House of Representatives by October 1, 2025, that recommends 557
835	835	a targeted area of research for 5 years, beginning January 1, 558
836	836	2026, and ending December 31, 2030, for the awarding of funds. 559
837	837	(13) The department shall establish criteria a nd allocate 560
838	838	funds beginning January 1, 2026, and each year thereafter until 561
839	839	2030, for conducting research on the targeted area of cancer 562
840	840	recommended by the report as described in (12). 563
841	841	(14) The collaborative must only allocate funds for 564
842	842	research in the targeted area of cancer recommended by the 565
843	843	report as described in (12). 566
844	844	(15) Beginning July 1, 2026, each allocation agreement 567
845	845	issued by the department relating to the Cancer Connect 568
846	846	Collaborative Research Incubator payments under subsection (11) 569
847	847	must include all of the following: 570
848	848	(a) A line-item budget narrative documenting the annual 571
849	849	allocation of funds to a recipient. 572
850	850
851	851	HB 1347 2025
852	852
853	853
854	854
855	855	CODING: Words stricken are deletions; words underlined are additions.
856	856	hb1347-00
857	857	Page 24 of 25
858	858	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
859	859
860	860
861	861
862	862	(b) A cap on the annual award of 15 percent for 573
863	863	administrative expenses. 574
864	864	(c) A requirement for the recipient to submit quarterly 575
865	865	reports of all expenditures made by the recipient with funds 576
866	866	received through the Cancer Connect Collaborative Research 577
867	867	Incubator. 578
868	868	(d) A provision to allow the department and other state 579
869	869	auditing bodies to audit all financial records, supporting 580
870	870	documents, statistical records, and any other documents 581
871	871	pertinent to the allocation agreement. 582
872	872	(e) A provision requiring the annual reporting of outcome 583
873	873	data and protocols used in achieving those outcomes. 584
874	874	(16)(a) Beginning July 1, 2027, and each year thereafter 585
875	875	until 2031, the collaborative shall submit a report to the 586
876	876	Governor, President of the Senate, and Speaker of the House of 587
877	877	Representatives that evaluates research conducted through the 588
878	878	Cancer Connect Collaborative Research Incubator and presents 589
879	879	statuses and findings. 590
880	880	(b) The final report submitted on July 1, 2031, must 591
881	881	include all of the following: 592
882	882	1. A summary of all results from the research completed or 593
883	883	the status of research in progress. 594
884	884	2. An evaluation of all research conducted under the 595
885	885	Cancer Connect Collaborative Research Incubator, beginning 596
886	886	January 1, 2026. 597
887	887
888	888	HB 1347 2025
889	889
890	890
891	891
892	892	CODING: Words stricken are deletions; words underlined are additions.
893	893	hb1347-00
894	894	Page 25 of 25
895	895	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
896	896
897	897
898	898
899	899	3. Recommendations for future areas of cancer research. 598
900	900	(17)(12) This section is subject to annual appropriation 599
901	901	by the Legislature. 600
902	902	(18)(13) The department may adopt rules to admi nister this 601
903	903	section. 602
904	904	Section 2. This act shall take effect July 1, 2025. 603